Effects of OK-432 (Picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432

Oncology (Switzerland)

Volumn 54, Issue 5, 1997, Pages 414-423

  Aoyagi, Hidetada ^a   Iino, Yuichi ^a   Takeo, Takeshi ^a   Horii, Yoshio ^a   Morishita, Yasuo ^a   Horiuchi, Ryuya ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

DP TAT 59; Estrogen receptor; Krestin; Lentinan; MCF 7; OK 432; Picibanil; Progesterone receptor; Tamoxifen

Indexed keywords

ANTIESTROGEN; BIOLOGICAL RESPONSE MODIFIER; ESTROGEN RECEPTOR; KRESTIN; LENTINAN; PICIBANIL; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECEPTOR BINDING; SCATCHARD PLOT; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; PICIBANIL; PROGESTERONE; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030795073     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227728     Document Type: Article

References (64)

1. Hortobagy GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richiman SP, Hearsh EM; Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 1979:44: 1955-1962.
2. Klefstrim P: Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer. Cancer Treat Rep 1980; 64:65-72.
3. Grohn P, Heinonen E, Klefstrim P, Tarrkanen J: Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1984:54:670-674.
4. Lytle GH, McGee JM, Yamanashi WS, Malnar K, Bellcfeuill C, Humphrey LJ: Five-year survival in breast cancer treated with adjuvant immunotherapy. Am J Surg 1994; 168:19-21.
5. Factors influencing the response and survival of patients with liver métastasés from breast cancer receiving OK-432 combined adoptive immunotherapy. J Cancer Res Clin Oncol 1992:118:157-162.
6. Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Harnada Y, Morimoto T, Ogawa N: Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon Group of the Adjuvant Chemo-Endocrine Therapy for Breast Cancer Organization. Cancer 1992:70:2475-2483.
7. Tominaga T, Kitamura M, Saito T, Itho I: Inhibitory effect of levamisole on rat mammary tumorigenesis by 7, l2-dimcthylbenz[a]an-thracenc. Prog Med 1982;2:735-739.
8. Kosaka A, Kuzuoka M, Yamafuji K, Imaizumi A, Hattori Y, Yamashita A: Synergistic action of lentinan (LNT) with endocrine therapy of breast cancer in rats and human. Gan To Kagaku Ryoho 1987;14:516-522.
9. Kan N, Yamasaki S, Kodama H, Okino T, Ichi-nosc Y, Moriguchi Y, Li L, Sugie T, Imamura M: Bone metastasis as a prognostic factor in breast cancer patients with liver metastasis given OK-432-combined adoptive immunothcra-pv via the hepatic arterv. Biotherapy 1993:6: 245-250.
10. Nakane Y, Okino K, Kodama M: Immunotherapy with OK-432. Picibanil for breast cancer (in Japanese). Jpn J Breast Cancer 1987;2:11-20.
11. Nomura Y, Tashiro D, Shinozuka K: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 1981:55:546-551.
12. Okamoto H, Shoin S, Koshimura S, Shimizu R: Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967;11:323-336.
13. Okamoto H, Minami M, Shoin S, Koshimura S, Shimizu R: Experimental anticanccr studies. Part XXXI. On the streptococcal preparation having potent anticancer activity. Jpn J Exp Med 1966;36:175-186.
14. Uchida A, Hoshino T: Clinical studies on cell-mediated immunity in patients with malignant diseases. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer 1980:45:476-483.
15. Watanabc Y, Iwa T: Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 1984:53:248- 253.
16. Kimura I, Ohnoshi T, Yasuhara S, Sugiyama M, Urabe Y, Fujii M, Machida K: Immunochc-motherapy in human lung cancer using the streptococcal agent OK-432. Cancer 1987;37: 2201-2203.
17. Cervical Cancer Immunotherapy Study Group: Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cancer 1987;60:2397-2402.
18. Nakazawa S, Yoshino J, Okamura S, Yamao K: Clinical efficacy of endoscopic injections of OK-432 in the treatment of gastric cancer. Scand J Gastroenterol 1988:23:539-545.
19. Uchida A, Micksche M: Intrapleural administration of OK-432 in cancer patients: Activation of NK cell and reduction of suppressor cells. Int J Cancer 1983;31:1-5.
20. Torisu M, Katano Y, Itho H: New approach and management of malignant ascites with a streptococcal preparation. OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983;93:357-373.
21. Katano M, Torisu M: New approach and management of malignant ascites with a streptococcal preparation, OK-432. II. lntraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 1983;93:365-373.
22. Chirigos M, SaitoT, Almadgc JE, Budzynki W, Gruys E: Cell regulatory and immunorestor-ative activity of picibanil (OK-432). Cancer Detect PrevSuppl 1987;1:317-328.
23. Uchida A, Wicksche M. Hoshino T: Intrapleural administration of OK-432 in cancer patients: Augmentation of autologous tumor-killing activity of tumor-associated large granular lymphocytes. Cancer Immunol Immunother 1984;18:5-12.
24. Uchida A, Micksche M: Suppressor cells for natural killer activity in carcinomatous pleural effusions of cancer patients. Cancer Immunol Immunother 1981:11:255-263.
25. Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitu Y, Urushizaki I: Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology 1986;11:79-86.
26. Watanabc N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizakii U., Yamamoto A. Nagamu-ta M, Sugawara Y: Therapeutic elTcct of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients. Immunopharma-col lmmunotoxicol 1988;10:53-65.
27. Nakashima J, Tachibana M, Baba S, Deguchi N, Jitsukawa S, Hata M, Tazaki H: Studies on the production of endogenous cytokines in patients with renal cell carcinoma. Nippon Hin-yokika Gakkai Zasshi 1992;83:1110-1117.
28. Saito M, Yamaguchi T, Ebina T, Koi M, Aonu-ma E, Usami H, Ishida N: In vitro production of immune interfcron-gamma (IFN y) by murine spleen cells when different sensitizing antigens are used in vivo and in vitro. Cell Immunol 1983;78:379-386.
29. Matumoto H, Izutani R, Terada M, Noguchi J, Shiraha S, Kuyama T, Aoki N: OK-432-in-duced production of IFN-gamma in peripheral mononuclear cells from healthy subjects and patients with cancer. Nippon Gan Chiryo Gakkai Shi 1989;24:751-758.
30. Saito M, Ebina T, Koi M, Yamaguchi T, Ka-wade Y, Ishida N: Induction of interferon-y in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 1982: 68:187-192.
31. Hoshino T, Uchida A: Effective mechanisms of BRM. with special reference to induction of autologous tumor cell-killing (ATK) activity by OK-432. Gan To Kagaku Ryuho 1986:13: 1277-1284.
32. Uchida A, Klein E: Activation of human blood lymphocytes and monocytes by the streptococcal preparation OK-432: Enhanced generation of soluble cytotoxic factors. Immunol Lett 1985;10:177-181.
33. Bonavida B, Katz J, Hoshino T: Mechanism of NK activation by OK-432 (Streptococcus pyogenes). 1. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with target cells. Cell Immunol 1986:102:126-135.
34. Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N: Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J 1m-munopharmacol 1986;7:263-270.
35. Aiba S, Tagami H: Proliferative responses of peripheral blood mononuclear cells from psoriatic patients to T lymphocyte-stimulating cytokines (IL-2, IL-3,1L-4, and granulocyte-mac-rophagc colony-stimulating factor) and OK-432. Arch Dermatol Res 1989;281:310-315.
36. Fukui H, Koishihara Y, Nagamuta M, Mizu-tani Y, Uchida A: Production of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432. Immunol Lett 1989:21:127-130.
37. Ichimura O, Suzuki S, Sugawara Y, Osawa T: Characterization of mouse natural killer cell activating factor (NKAF) induced by OK-432: Evidence for interferon- and interleukin 2-independent NK cell activation. Br J Cancer 1984;50:97-108.
38. Herberman RB, Djeu JY, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fa-gnani R, Santoni A. Puccetti P: Natural killer cells: Characteristics and regulation of activity. Immunol Rev 1979;44:43-70.
39. Hirosc K, Zachariae CO, Oppenhcim JJ, Mat-sushisma K: Induction of gene expression of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lym-phokinc Res 1990;9:475-483.
40. Sakagami H, Sugaya K, Utsumi A, Fujinaga S, Sato T, Takeda M: Stimulation by PSK of interleukin-1 production by human peripheral blood mononuclear cells. Anticanccr Res 1993; 13:671-675.
41. Taguchi T: Clinical efficacy of lentinan on patients with stomach cancer: End point results of a four-year follow-up survey. Cancer Detect PrevSuppl 1987;1:333-349.
42. Wakui A, Kasai M, Konno K, Abe R, Kanamu-ra R, Takahashi K, Nakai Y, Yoshida Y, Koie H, Masuda H: Randomized study of lentinan on patients with advanced gastric and colorectal cancer (in Japanese). Gan To Kagaku Ryo-ho 1986;13:1050-1059.
43. Chihara G, Harano J, Maeda Y, Shiio T, Suga T, Takasuka N, Sasaki T: Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: An overview. Cancer Detect PrevSuppl 1987;1:423-443.
44. Fruehauf JP, Bonnard GD, Herbcrman RB: The effect of lentinan on production of inter-leukin-1 by human monocytes. Immunophar-macology 1982;5:65-74.
45. Miyakoshi H, Aoki T: Acting mechanisms of lentinan in human. II. Enhancement of nonspecific cell-mediated cytotoxicity as an interferon inducer, Int J lmmunopharmacol 1984:6: 365-371.
46. Scholl SM, Huff KK, Lippman ME: Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology 1983;113:611-617.
47. Kurcbayashi J, Horiuchi R, Aoyagi H, Nakamura T, Iino Y, Ishida T, Takikawa H, Izuo M: A new simple sensitivity test of anticanccr drugs in cancer treatment using a 96-well filtration plate (in Japanese). Oncologia 1989:22: 55-61.
48. Setaro F, Morley CGD: A modified fiuoromet-ric method for the determination of microgram quantities of DNA from cell or tissue cultures. Anal Biochem 1976;71:313-317.
49. Taylor CM, Blanchard B, Zava DT: A simple method to determine whole cell uptake of radiolabelled oestrogen and progesterone and their subcellular localization in breast cancer cell lines in monolayer culture. J Steroid Bio-chem 1984;20:1083-1088.
50. Kurebayashi J, Horiuchi R, Nakamura T, Iino Y, Takikawa H, Izuo M: Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method (in Japanese). Nippon Naibunpi Gakkai Zasshi 1987; 63:1351-1363.
51. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:600-672.
52. Tominaga T, Yoshida Y, Matsumoto A, Haya-shi K, Kosaki G: Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro. Anticancer Res 1993;13:661-665.
53. Van Den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J: Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen. Br J Cancer 1987;55:25-27.
54. Sica G, Natoli V, Stella C. DelBianco S: Effect of natural beta-intcrferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 1987;60:2419-2423.
55. Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Fridman WH, Magdelenat H, Falcoff E, Bil-liau A: Administration of fibroblast interferon to patients with advanced breast cancer: Possible effects on skin metastasis and on hormone receptors. Eur J Cancer 1982;18:929-935.
56. Batra S, Bengstonn B: Effects of diethylstilbes-trol and ovarian steroids on the contractile movements in rat uterine smooth muscle. J Physiol 1978;276:329-342.
57. Goldstein D, Bushmcyer SM, Witt PL, Jordan VC, Borden EC: Effects of type I and type II interferons on cultured human breast cells: Interactions with estrogen receptors and with tamoxifen. Cancer Res 1989;49:2698-2702.
58. Clark JW, Longo DL: Interferons in cancer therapy; in DeVita VT Jr. Heilman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology Updates. Philadelphia, Lippin-cott, 1987, vol 2, No 4. pp 1-16.
59. Gutterman JU, Blumenschein GR, Alcxanian R, Yap H-Y, Rasmussen SL, Harmon M, Kramer M, Pestka S: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980;93: 399-406.
60. Borden EC, Holland JF, Dao TL, Gutterman JU, Wiener L, Chang Y-C, Patel J: Leukocyte-derived interferon (alpha) in human breast carcinoma. Ann Intern Med 1982;97:1-6.
61. Shcrwin SA, Mayer D, Ochs JJ, Abrams PG, Knot JA, Foon KA, Fein S, Oldham RK: Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. Ann Intern Med 1983;98:598-602.
62. Muss HB, Kempf RA, Martino S, Rudnick SA, Greiner J, Cooper MR, Decker D, Grunbcrg SM, Jackson DV, Richards F II. Samal B, Singhakowinta A, Spurr CL, Stuart JJ, White DR. Caponera M, Mitchell MS: A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J Clin Oncol 1984;2:1012-1016.
63. Wälder S, Lyver A, Goldman M, Wiemik PH: Therapy with 5-fluorouracil and recombinant alpha-2a-interferon in refractory GI malignancies (abstract). Proc Am Soc Clin Oncol 1989;8: 99.
64. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrucno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff I: 13-cis Reti-noic acid plus interferon a-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992,84:241-245.